Search - tctmd.com

Displaying 501 - 520 of 671

Sort: Relevancy | Date

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Presentation TCT 2013

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Presenter: Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Albert Shen, Vicken Aharonian, Prakash Mansukhani, Gregg Stone, Martin Leon, Jeffrey Moses, Naing Moore, Ric Hyett, Richard Contreras, Somjot Brar

January 31, 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci

January 31, 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

Presentation TCT 2013

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

Presenter: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Amro Elnagar, Sung Il Im, Sun Won Kim, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong

January 31, 2013

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Presentation

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Presenter: Marco Valgimigli

January 16, 2013

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms, Noncompliance, Diet, Smoking, Co-medications, and Preexistent Variability in Platelet Func

Presentation

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms, Noncompliance, Diet, Smoking, Co-medications, and Preexistent Variability in Platelet Func

Presenter: Andrew L. Frelinger

January 15, 2013

Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in ACS Patients Undergoing PCI

Presentation

Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in ACS Patients Undergoing PCI

Presenter: J.P. Loh

January 09, 2013

Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

Presentation

Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

Presenter: A. Wittfeldt

January 08, 2013

Reduction in First and Recurrent Cardiovascular Events with Ticagrelor vs. Clopidogrel

Presentation

Reduction in First and Recurrent Cardiovascular Events with Ticagrelor vs. Clopidogrel

Presenter: P. Kohli

January 06, 2013

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Presentation

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Presenter: J. Yu

December 17, 2012

Association of Clopidogrel Pretreatment with Mortality, CV Events, and Major Bleeding After PCI

Presentation

Association of Clopidogrel Pretreatment with Mortality, CV Events, and Major Bleeding After PCI

Presenter: A. Bellemain-Appaix

December 17, 2012

Bioequivalence in the Real World Is a Complex Challenge: The Case of Clopidogrel

Presentation

Bioequivalence in the Real World Is a Complex Challenge: The Case of Clopidogrel

Presenter: Rossella Marcucci

December 12, 2012

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

Bivalirudin for Primary PCI

Presentation

Bivalirudin for Primary PCI

Presenter: B. Hibbert

November 26, 2012

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Presentation

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Presenter: Eric L. Eisenstein

November 19, 2012

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Presentation

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Presenter: C. Quintavalle

November 15, 2012

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Presentation

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Presenter: A. Sachdeva

November 13, 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.